European Cancer Care: Balancing Economic Stability with Improved Survival Rates
European Cancer Care has achieved substantial improvements in survival rates without a disproportionate escalation in health budgets, as evidenced by the Comparator Report on Cancer in Europe 2025 from the Swedish Institute for Health Economics (IHE), commissioned by the EFPIA Oncology Platform. Cancer accounts for 23% of all deaths and 17% of disability-adjusted life years (DALYs) yet comprises only 6–7% of total health expenditure, a stable share over three decades. The report highlights a shift from high indirect costs, such as productivity losses, to manageable direct healthcare costs, resulting in a stable economic burden per new patient of €69,000–79,000 since 1995.
Modest Spending Share Unlocks Survival Gains
The report reveals that European Cancer Care’s 6–7% share of total health spending has remained constant for 30 years, despite its significant disease burden, challenging perceptions of financial unsustainability. From 1995 to 2023, direct healthcare costs doubled to €146 billion, but indirect costs from sick leave, early retirement, and premature death fell from €97 billion to €82 billion, driven by better outcomes that preserve workforce participation. Total economic costs rose 43%, mirroring a 60% increase in cancer incidence, thus stabilizing the per-patient burden and demonstrating value for money through efficiency gains.
Expenditure Shifts Boosting Efficiency
A key trend is the reallocation within cancer spending, with reduced inpatient hospital costs offset by increased outpatient care and medicines, enabling shorter stays, better side-effect management, and fewer recurrences. Innovations like oral and subcutaneous treatments have replaced lengthy intravenous infusions, paradoxically allowing higher medicine spending to generate system-wide savings. Spending varies nearly threefold across countries—below €150 per capita (PPP-adjusted) in Bulgaria and Romania, over €400 in Germany and Switzerland—with higher levels correlating to superior survival, though diminishing returns emphasize the need for efficient allocation.
Robust Methods Grounding Burden Insights
The IHE report employs a comprehensive framework comparing direct healthcare costs against indirect societal costs across Europe from 1995 to 2023, drawing on national health accounts and productivity loss estimates to contextualize cancer’s 17% DALY share. It tracks incidence-adjusted economic burdens and survival metrics, such as five-year rates nearing 90% for breast and prostate cancers but below 30% for lung cancer, using PPP-adjusted per capita spending for cross-country comparability. This methodology underpins claims of stability, revealing how treatment advances have shifted visible costs into health systems while reducing hidden productivity losses.
Investments Fueling Policy Wins
These findings imply that oncology investments yield high returns, supporting market access and reimbursement for innovative therapies that optimize total economic burden rather than direct costs alone. The stability of per-patient costs validates current approaches, where higher medicine expenditures enable broader savings, aligning with trends toward outpatient shifts and efficiency metrics. In outcomes research terms, the correlation between spending and survival underscores prioritizing “wise spending” to address gaps in hard-to-treat cancers, informing Ministries of Health and Finance to sustain progress without budget overload, while highlighting convergence opportunities for lower-spending nations. Overall, the report reframes European Cancer Care as a model of value delivery, poised for further gains through targeted, evidence-driven policies.
